J Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION
|
|
- Jared Freeman
- 7 years ago
- Views:
Transcription
1 VOLUME 26 NUMBER 31 NOVEMBER JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Outcome After Surgical Resections of Chest Wall Sarcomas Michael W. Wouters, Albert N. van Geel, Lotte Nieuwenhuis, Harm van Tinteren, Cees Verhoef, Frits van Coevorden, and Houke M. Klomp From the Departments of Surgical Oncology and Medical Statistics, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam; and the Department of Surgical Oncology, Erasmus Medical Center, Daniel den Hoed kliniek, Rotterdam, the Netherlands. Submitted March 31, 2008; accepted June 10, 2008; published online ahead of print at on September 15, Authors disclosures of potential conflicts of interest and author contributions are found at the end of this article. Corresponding author: Michael W. Wouters, MD, the Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; m.wouters@nki.nl by American Society of Clinical Oncology X/08/ /$20.00 DOI: /JCO A B S T R A C T Purpose Sarcomas of the chest wall are rare, and wide surgical resection is generally the cornerstone of treatment. The objective of our study was to evaluate outcome of full-thickness resections of recurrent and primary chest wall sarcomas. Patients and Methods To evaluate morbidity, mortality, and overall and disease-free survival after surgical resection of primary and recurrent chest wall sarcomas, we performed a retrospective review of all patients with sarcomas of the chest wall surgically treated at two tertiary oncologic referral centers between January 1980 and December Patient, tumor, and treatment characteristics, as well as the follow-up of these patients, were retrieved from the patients original records. Results One hundred twenty-seven patients were included in this study, 83 patients with a primary sarcoma and 44 patients with a. Age, sex, tumor size, histologic type, grade and localization on the chest wall were similar for both groups. Fewer neoadjuvant and adjuvant therapies were used in the treatment of s. Chest wall resection was more extensive in the recurrent group, which did not result in more complications (23%) or more reinterventions (5%). Microscopically radical resection was achieved in 80% of the primary sarcomas and 64% of the s. With a median follow-up of 73 months, disease-free survival after surgery for s was 18 months versus 36 months for primary sarcomas, with 5-year survival rates of 50% and 63%, respectively. Conclusion Although chances for local control are lower after surgical treatment of recurrent chest wall sarcoma, chest wall resection is a safe and effective procedure, with an acceptable survival. J Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION Sarcomas account for approximately one percent of all malignancies in adults. Only 10% to 15% arise in the chest wall. Generally, surgical resection is the treatment of choice, with a wide full-thickness chest wall resection, a skeletal reconstruction, and soft tissue coverage. may be preceded or followed by radiotherapy or chemotherapy. Parallel to the extent of the resection, the rigidity of the chest wall is affected, which can lead to significant morbidity and even mortality. This could especially be true for resections of s after previous chest wall resection. In the literature, few data are available regarding the appropriate management of patients with recurrent sarcomas of the chest wall. 1 Most series are heterogeneous, describing resections for sarcoma as well as carcinoma, without distinguishing primary, recurrent, and metastatic disease. To our knowledge, the largest series of recurrent chest wall sarcomas described 17 patients. 2 To analyze the safety and effectiveness of chest wall resections for primary and recurrent sarcoma, we evaluated morbidity, mortality, and oncologic outcome of a consecutive series of chest wall resections from two tertiary referral centers in the Netherlands. PATIENTS AND METHODS From the histopathologic results in file of the department of Pathology of the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital and the Erasmus Medical Center/Daniel den Hoed Clinic, 133 consecutive full-thickness chest wall resections for sarcoma were identified. Both hospitals are referral centers for the treatment of soft tissue 2008 by American Society of Clinical Oncology 5113
2 Wouters et al tumors in the Netherlands. Resections were performed between January 1980 and December Pretreatment patient evaluation included medical history and physical examination, baseline assessment of pulmonary function, chest x-ray, and magnetic resonance imaging or computed tomography of the chest wall tumor site. Patients were seen by oncologic surgeons (mainly F.v.C. and A.N.v.G.) for assessment of feasibility of primary resection or reexcision surgery. The appropriateness of neoadjuvant and adjuvant radiation or chemotherapy treatment was discussed in multidisciplinary teams. Resection of either primary or recurrent sarcoma was performed with an intentional 1- to 2-cm margin of normal soft tissue surrounding the mass, wherever feasible. In cases in which the tumor was in proximity to functionally significant but not directly involved neurovascular structures, the margin could be less than 1 cm. For this study, we defined chest wall sarcoma as any sarcoma involving ribs, sternum, costovertebral junction, or vertebral body. Tumors of the clavicle or scapula, without expansion into the ribs or sternum, were excluded. Retrospectively, patient, tumor, and treatment characteristics of Table 1. Patient, Tumor, and Treatment Characteristics of Chest Wall Resections for Sarcoma (n 83) (n 44) Characteristic No. of Patients % No. of Patients % Age, years Median Range Sex Male Female Histology Chondro/osteosarcoma Liposarcoma Fibrosarcoma Pleiomorphic sarcoma Leiomyosarcoma Angiosarcoma Sarcoma NOS Other Tumor grade Low Intermediate High Unknown Location Ventral Lateral Dorsal Sulcus superior Neoadjuvant treatment None Chemotherapy Radiotherapy Intention of surgery Curative Salvage Skeletal resection Ribs Median Range Sternum Other (vertebra, scapula, clavicle, four quarter) Reconstruction None Mesh alone Omentum Myocutaneous flap Unknown Adjuvant treatment Radiotherapy Chemotherapy Total No. of patients Abbreviation: NOS, not otherwise specified by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
3 Outcome After Resection of Chest Wall Sarcomas Table 2. Outcome After Chest Wall Resections for Sarcoma Outcome No. of Patients % No. of Patients % Complications None Bleeding Infectious Reconstructive failure Pulmonary Cardiac Other Reoperations Hospital stay, days Median 9 12 Maximum In-hospital mortality Margins R R R Unknown Recurrence None Local Distant Median disease-free survival, months Median survival, months Median follow-up, months Total No. of patients patients were retrieved from the patients original records, completed with detailed information about postoperative morbidity and mortality. Patients were classified to the primary sarcoma group when a fullthickness chest wall resection for a primary sarcoma was performed in the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital or the Erasmus Medical Center/Daniel den Hoed Clinic. Patients belonged to the recurrent sarcoma group when they presented with a recurrent sarcoma or had only a superficial chest wall resection for the primary tumor. Two independent investigators reviewed the pathology reports (L.N. and M.W.W.). A macroscopically irradical (R2) resection was defined as gross irresectable tumor or spill, and a microscopically positive (R1) margin was defined as tumor extension to the inked margin on permanent histopathologic Chest wall sarcomas (N = 127) sarcomas (n = 83; 65%) sarcomas (n = 44; 35%) Recurrence (n = 41; 49%) Disease free (n = 42; 51%) Disease free (n = 11; 25%) 2nd (n = 33; 75%) Fig 1. Recurrence patterns after chest wall resection for primary and recurrent sarcoma. Local (n = 17; 41%) Local and distant (n = 3; 7%) Distant (n = 21; 51%) Local (n = 20; 61%) Local and Distant (n = 1; 3%) Distant (n = 12; 36%) (n = 5; 29%) (n = 12; 60%) by American Society of Clinical Oncology 5115
4 Wouters et al sections. Cases in which tumors did not extend to the inked margin were considered to have microscopically negative (R0) margins. Follow-up information was retrieved from the patients original records. Incidence, type, and time of, as well as localization and treatment of s, were entered into the database. Kaplan and Meier analysis was used to estimate overall survival (OS) and disease-free survival (DFS). Survival times were calculated from the date of operation. Differences in survival were estimated by log-rank analysis. All statistical analyses were performed using the statistical software package SPSS, version 15.0 (SPSS, Chicago, IL). during follow-up. These distant metastases mainly occurred in the lungs (14 of 21 patients and nine of 12 patients, respectively). Other locations were bone, liver, and brain. The treatment of metastases with combinations of chemotherapy, surgery, or radiotherapy was similar in both groups. In the absence of distant metastases, second local s were often treated surgically, but reresections were performed more often in the group (60%) than in the primary group (29%), as shown in Figure 2. RESULTS Of the 133 patients in our series, 83 patients underwent chest wall resection for primary sarcoma, 44 patients underwent chest wall resection for recurrent sarcoma, and six patients underwent chest wall resection for a distant metastasis in the chest wall. These six patients were excluded. In the recurrent sarcoma group, 35 patients had a previous full-thickness chest wall resection. Nine patients underwent a superficial resection for their primary sarcoma (primary resection regarded to be radical). Patient and tumor characteristics are listed in Table 1. There were only minor differences in age, sex, comorbidities, histologic type, localization, and grade between patients in the primary sarcoma group and in the group. Neoadjuvant and adjuvant therapies were used more often in the primary than in the group. Especially chemotherapy was delivered more often in the primary sarcoma group as a part of a multimodality treatment. Two patients in the primary sarcoma group and one patient in the recurrent group underwent salvage surgery. In all other patients, a chest wall resection was performed with a curative intent. Additional to earlier resections, a median number of 2.4 ribs were resected in the group, which is similar to the number of resected ribs in the primary sarcoma group. In patients in whom no additional ribs were resected, another part of the bony thorax was excised, for example, part of the sternum. The skeletal reconstructions to cover the defect in the chest wall are listed in Table 1. Postoperative morbidity was similar in the two groups. Operative reintervention for complications was performed in three patients in the primary sarcoma group and in two patients in the group. Median hospital stay was 3 days longer for patients in the group (Table 2). R0 resection was achieved in 80% of patients with a primary chest wall sarcoma and in 61% of the patients with a recurrent sarcoma. With a median follow-up time of 73 months, almost half of the patients with recurrent sarcomas had a second on the chest wall (48% as compared with 24% in the primary group). Only 25% of patients with a resection for recurrent sarcoma remained tumor free, as compared with 51% of the patients after a primary resection. In the group of patients who underwent surgery for, considerably more local than distant s were seen. Of all patients with irradical resections, 86% developed recurrent disease (94% in the group and 63% in the primary group). Figure 1A shows the DFS curves: median DFS was 36 months after resection for primary sarcoma and 18 months after resection of recurrent sarcoma. OS is shown in Figure 1B. In both groups, approximately one of four patients (25% v 27%) developed distant metastases DISCUSSION We analyzed the results of 127 full-thickness resections for chest wall sarcoma, of which 44 were performed for. Analysis A B Disease-Free Survival (probability) Overall Survival (probability) Time From (months) Time From (months) Fig 2. (A) Disease-free survival and (B) overall survival of patients after chest wall resections for primary and recurrent sarcomas by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
5 Outcome After Resection of Chest Wall Sarcomas showed that a full-thickness surgical resection is a safe and effective procedure, with a limited number of complications, and is associated with adequate long-term survival, even for recurrent chest wall sarcoma. Sarcomas of the chest wall are uncommon. The available literature consists of a number of series, often with mixed differentiation (sarcoma/carcinoma), histologic subtype, and presentation as a primary or recurrent sarcoma. Reviewing the literature, we found 16 articles reporting outcome after full-thickness chest wall resections for malignancies (Table 3). Seven of these series included not only sarcomas, but also resections for carcinoma, like locally advanced breast or lung cancer. 5,9,15,16 Gordon et al 13 described the results of 149 cases of chest wall sarcomas surgically treated in the Memorial Sloan- Kettering Cancer Center between 1948 and Only nine resections for recurrent sarcoma were included in this series, and these were not separately analyzed. Gross et al 2 described the largest series of recurrent chest wall sarcomas, concerning 17 patients surgically treated for a in a series of 55 chest wall resections. This group of patients had a 5-year DFS rate of 66%. In our series, 44 chest wall resections for recurrent sarcoma were identified; 43 patients had a resection with curative intent. In comparison to the primary sarcoma group, localization, size, grade, and the number of ribs resected were not different (Table 1). sarcomas were less often treated with neoadjuvant or adjuvant chemotherapy, because an isolated local mainly needs local therapy. Morbidity of resections for was similar to that of resections for primary sarcoma (Table 2). With a complication rate of 21% and only 5% of patients needing operative reintervention, full-thickness chest wall resection can be considered a safe procedure for primary sarcomas as well as recurrent disease. Our study has several limitations. Although this is one of the largest series in the literature, patient groups are still relatively small and heterogeneous. Combination of data from different tertiary referral centers may solve part of this problem. Centralized and multidisciplinary treatment of these rare tumors and prospective evaluation of interventions may improve our understanding of factors leading to successful treatment. This retrospective study covers 26 years of chest wall resections for sarcoma in two different tertiary referral centers. In this period, imaging techniques have improved (eg, computed tomography and magnetic resonance imaging) and different treatment protocols have been used, although wide local excision of the tumor has always been the cornerstone of treatment. Selection bias can be part of encouraging survival rates in recurrent sarcomas, because only locally recurrent sarcomas, with a favorable course of the disease (no distant metastases), were selected for surgery. Obviously there were differences in oncologic outcome between the group of patients with a primary sarcoma and those with a. Along with the number of microscopically irradical resections, DFS was significantly less for patients who underwent surgery for recurrent sarcoma. With a similar rate of distant metastases occurring during follow-up, the incidence of local was two-fold higher in the recurrent sarcoma group (48% v 24%). In surgical procedures for recurrent disease, it may be more difficult to obtain tumor-free margins as a result of fibrosis caused by earlier resections and restrictions of the respiratory function in relation to the rigidity of the chest wall. However, tumor-free margins are critical, because 86% of irradical resections result in. This is especially true in the recurrent group: 93% of irradical resections were followed by a re, often presenting as an isolated local on the chest wall without distant metastases. Surgical treatment of these second s is performed in 60% of these patients (Fig 2). Favorable OS supports these repeated attempts to obtain local control. In this series, 5-year survival after resections for recurrent chest wall sarcoma was 50%, as compared with 63% for primary chest wall sarcomas. These survival rates support surgical resection or reresection of any sarcoma of the chest wall, if technically possible. Because local is the main problem in these resections, radiotherapy may improve local control rates in some cases. The decision to offer patients a combination of radiotherapy and surgery Table 3. Studies on Chest Wall Resections for Sarcoma First Author Year of Study Study Period (years) Chest Wall Malignancy Sarcoma Sarcomas Wouters (current study) Pfannschmidt Gross Chapelier Chang Unknown Walsh Warzelhan Unknown Sabanathan Incarbone Martini Chapelier Burt Gordon Perry King Unknown Pairolero Graeber Unknown by American Society of Clinical Oncology 5117
6 Wouters et al requires careful patient selection and planning. Although radiation carries clinically significant risks of wound complications, fibrosis, and pulmonary toxicity, patients, especially those who are at high risk of local or compromised margins, may benefit from intensified local treatment. Unfortunately, only some sarcomas of the chest wall are radiosensitive. In conclusion, surgical resection of chest wall sarcoma is a safe and effective procedure, with acceptable long-term survival, even for recurrent sarcomas. Local control rates need attention and may be improved by intensified multimodality treatment. AUTHORS DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The author(s) indicated no potential conflicts of interest. AUTHOR CONTRIBUTIONS Conception and design: Michael W. Wouters, Albert N. van Geel Provision of study materials or patients: Michael W. Wouters, Albert N. van Geel, Cees Verhoef, Frits van Coevorden, Houke M. Klomp Collection and assembly of data: Michael W. Wouters, Lotte Nieuwenhuis Data analysis and interpretation: Michael W. Wouters, Albert N. van Geel, Lotte Nieuwenhuis, Harm van Tinteren, Cees Verhoef, Frits van Coevorden, Houke M. Klomp Manuscript writing: Michael W. Wouters, Albert N. van Geel, Lotte Nieuwenhuis, Harm van Tinteren, Cees Verhoef, Frits van Coevorden, Houke M. Klomp Final approval of manuscript: Michael W. Wouters, Albert N. van Geel, Lotte Nieuwenhuis, Harm van Tinteren, Cees Verhoef, Frits van Coevorden, Houke M. Klomp REFERENCES 1. Perry RR, Venzon D, Roth JA, et al: Survival after surgical resection for high-grade chest wall sarcomas. Ann Thorac Surg 49: , Gross JL, Younes RN, Haddad FJ, et al: Soft-tissue sarcomas of the chest wall: Prognostic factors. Chest 127: , Pfannschmidt J, Geisbusch P, Muley T, et al: Surgical treatment of primary soft tissue sarcomas involving the chest: Experiences in 25 patients. Thorac Cardiovasc Surg 54: , Chapelier AR, Missana MC, Couturaud B, et al: Sternal resection and reconstruction for primary malignant tumors. Ann Thorac Surg 77: , Chang RR, Mehrara BJ, Hu QY, et al: Reconstruction of complex oncologic chest wall defects: A 10-year experience. Ann Plast Surg 52: , Walsh GL, Davis BM, Swisher SG, et al: A single-institutional, multidisciplinary approach to primary sarcomas involving the chest wall requiring full-thickness resections. J Thorac Cardiovasc Surg 121:48-60, Warzelhan J, Stoelben E, Imdahl A, et al: Results in surgery for primary and metastatic chest wall tumors. Eur J Cardiothorac Surg 19: , Sabanathan S, Shah R, Mearns AJ: Surgical treatment of primary malignant chest wall tumours. Eur J Cardiothorac Surg 11: , Incarbone M, Nava M, Lequaglie C, et al: Sternal resection for primary or secondary tumors. J Thorac Cardiovasc Surg 114:93-99, Martini N, Huvos AG, Burt ME, et al: Predictors of survival in malignant tumors of the sternum. J Thorac Cardiovasc Surg 111:96-105, Chapelier A, Macchiarini P, Rietjens M, et al: Chest wall reconstruction following resection of large primary malignant tumors. Eur J Cardiothorac Surg 8: , Burt M, Fulton M, Wessner-Dunlap S, et al: bony and cartilaginous sarcomas of chest wall: Results of therapy. Ann Thorac Surg 54: , Gordon MS, Hajdu SI, Bains MS, et al: Soft tissue sarcomas of the chest wall: Results of surgical resection. J Thorac Cardiovasc Surg 101: , King RM, Pairolero PC, Trastek VF, et al: chest wall tumors: Factors affecting survival. Ann Thorac Surg 41: , Pairolero PC, Arnold PG: Chest wall tumors: Experience with 100 consecutive patients. J Thorac Cardiovasc Surg 90: , Graeber GM, Snyder RJ, Fleming AW, et al: Initial and long-term results in the management of primary chest wall neoplasms. Ann Thorac Surg 34: , by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Clinical Indications and Results Following Chest Wall Resection
Clinical Indications and Results Following Chest Wall Resection for Recurrent Malignant Pleural Mesothelioma Ali SO, Burt BM, Groth SS, DaSilva MC, Yeap BY, Richards WG, Baldini EH and Sugarbaker DJ. Division
More informationL Lang-Lazdunski, A Bille, S Marshall, R Lal, D Landau, J Spicer
Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine and systemic chemotherapy in malignant pleural mesothelioma. A 10-year experience. L Lang-Lazdunski, A Bille, S Marshall, R Lal,
More informationAccelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl, Andrew Hope, Thomas K Waddell, Shaf Keshavjee,
More informationThe treatment and outcome of patients with soft tissue sarcomas and synchronous metastases
Sarcoma (2002) 6, 69 73 ORIGINAL ARTICLE The treatment and outcome of patients with soft tissue sarcomas and synchronous metastases JOHN M. KANE III, J. WILLIAM FINLEY, DEBORAH DRISCOLL, WILLIAM G. KRAYBILL
More informationPost-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence
Post- survival in completely resected stage I non-small cell lung cancer with local J-J Hung, 1,2,3 W-H Hsu, 3 C-C Hsieh, 3 B-S Huang, 3 M-H Huang, 3 J-S Liu, 2 Y-C Wu 3 See Editorial, p 185 c A supplementary
More informationMalignant pleural mesothelioma P/D vs. EPP
3 rd International Thoracic Oncology Congress Dresden, September 13 15, 2012 Malignant pleural mesothelioma P/D vs. EPP Walter Weder, MD Professor of Surgery Dokumentenname Datum Seite 1 Extrapleural Pneumonectomy
More informationLung Cancer Treatment Guidelines
Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,
More informationMesothelioma. Malignant Pleural Mesothelioma
Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency
More informationExtrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012
Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro Joon H. Lee 9/17/2012 Malignant Pleural Mesothelioma (Epidemiology) Incidence: 7/mil (Japan) to 40/mil (Australia) Attributed secondary to asbestos
More informationIntegrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
More informationManagement of spinal cord compression
Management of spinal cord compression (SUMMARY) Main points a) On diagnosis, all patients should receive dexamethasone 10mg IV one dose, then 4mg every 6h. then switched to oral dose and tapered as tolerated
More informationGUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
More informationManagement of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives. Dominique ELIAS
Management of Peritoneal Metastases (PM) from colorectal cancers: New Perspectives Dominique ELIAS Declaration of interest BOARDS Congress and teaching 0 Merck 0 Ipsen Novartis Sanofi Trials The peritoneum
More informationPET/CT in Lung Cancer
PET/CT in Lung Cancer Rodolfo Núñez Miller, M.D. Nuclear Medicine and Diagnostic Imaging Section Division of Human Health International Atomic Energy Agency Vienna, Austria GLOBOCAN 2012 #1 #3 FDG-PET/CT
More informationStage I Non-Small Cell Lung Cancer: Recurrence Patterns, Prognostic Factors and Survival
16 Stage I Non-Small Cell Lung Cancer: Recurrence Patterns, Prognostic Factors and Survival Jung-Jyh Hung and Yu-Chung Wu Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More informationMalignant Mesothelioma: an Update
Malignant Mesothelioma: an Update Nico van Zandwijk Asbestos Diseases Research Institute Bernie Banton Centre University of Sydney Australia Physicians Week RACP 19-5-2009 Health Risks of Asbestos Fibers
More informationMalignant Pleural Mesothelioma in Singapore
RESEARCH COMMUNICATION C SP Yip 1, HN Koong 2, CM Loo 3, KW Fong 1* Abstract Aim: To examine the clinical characteristics and outcomes of malignant pleural mesothelioma (MPM) in Singapore. Methods and
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationRadiotherapy in locally advanced & metastatic NSC lung cancer
Radiotherapy in locally advanced & metastatic NSC lung cancer Dr Raj Hegde. MD. FRANZCR Consultant Radiation Oncologist. William Buckland Radiotherapy Centre. Latrobe Regional Hospital. Locally advanced
More informationFunctional Outcomes of Reconstruction for Soft Tissue Sarcomas of the Foot and Ankle
Open Access Publication Functional Outcomes of Reconstruction for Soft Tissue Sarcomas of the Foot and Ankle by Emmanuel P. Estrella, MD 1, Edward HM Wang, MD, MSc 1, Leo Daniel D. Caro, MD 1, Vicente
More informationSurvival analysis of 220 patients with completely resected stage II non small cell lung cancer
窑 Original Article 窑 Chinese Journal of Cancer Survival analysis of 22 patients with completely resected stage II non small cell lung cancer Yun Dai,2,3, Xiao Dong Su,2,3, Hao Long,2,3, Peng Lin,2,3, Jian
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationMalignant Mesothelioma State of the Art
Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG
More informationSUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD
SUNY DOWNSTATE MEDICAL CENTER SURGERY GRAND ROUNDS February 28, 2013 VERENA LIU, MD ROSEANNA LEE, MD Case Presentation 35 year old male referred from PMD with an asymptomatic palpable right neck mass PMH/PSH:
More informationHow to treat early gastric cancer. Surgery
How to treat early gastric cancer Surgery Mark I. van Berge Henegouwen Department of Surgery, AMC, Amsterdam Director upper GI surgical unit Academic Medical Center Upper GI surgery at AMC 100 oesophagectomies
More informationGuidelines for the treatment of breast cancer with radiotherapy
London Cancer Guidelines for the treatment of breast cancer with radiotherapy March 2013 Review March 2014 Version 1.0 Contents 1. Introduction... 3 2. Indications and dosing schedules... 3 2.1. Ductal
More informationObjectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background
Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the
More informationMetastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.
Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases. Abstract This paper describes the staging, imaging, treatment, and prognosis of renal cell carcinoma. Three case studies
More informationMesothelioma. 1. Introduction. 1.1 General Information and Aetiology
Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are
More informationImage. 3.11.3 SW Review the anatomy of the EAC and how this plays a role in the spread of tumors.
Neoplasms of the Ear and Lateral Skull Base Image 3.11.1 SW What are the three most common neoplasms of the auricle? 3.11.2 SW What are the four most common neoplasms of the external auditory canal (EAC)
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationSeton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50
General Data Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 The vast majority of the patients in this study were diagnosed
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationManagement of low grade glioma s: update on recent trials
Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,
More informationCOMMISSIONING. for ULTRA-RADICAL SURGERY ADVANCED OVARIAN CANCER
COMMISSIONING for ULTRA-RADICAL SURGERY in ADVANCED OVARIAN CANCER WHY THIS MUST HAPPEN PERSPECTIVE COMMISSIONING FOR WHO, FOR WHAT? Biological Basis Surgical Basis International and national standards
More informationIntraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Volodymyr Labinskyy MD
Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Volodymyr Labinskyy MD KCHC 8/29/13 52 y.o. F presented with severe pain in the right back and right flank, sharp, 8 out of 10, for 7 days.
More informationORIGINAL ARTICLE THORACIC ONCOLOGY
Ann Surg Oncol (2013) 20:1934 1940 DOI 10.1245/s10434-012-2800-x ORIGINAL ARTICLE THORACIC ONCOLOGY Predictors for Locoregional Recurrence for Clinical Stage III-N2 Non-small Cell Lung Cancer with Nodal
More informationCurrent Status and Perspectives of Radiation Therapy for Breast Cancer
Breast Cancer Current Status and Perspectives of Radiation Therapy for Breast Cancer JMAJ 45(10): 434 439, 2002 Masahiro HIRAOKA, Masaki KOKUBO, Chikako YAMAMOTO and Michihide MITSUMORI Department of Therapeutic
More informationTable of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation
More informationRegular follow-up after curative resection of nonsmall cell lung cancer: a real benefit for patients?
Eur Respir J 2002; 19: 464 468 DOI: 10.1183/09031936.02.00231802 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Regular follow-up after curative
More informationCancer of the Cardia/GE Junction: Surgical Options
Cancer of the Cardia/GE Junction: Surgical Options Michael A Smith, MD Associate Chief Thoracic Surgery Center for Thoracic Disease St Joseph s Hospital and Medical Center Phoenix, AZ Michael Smith, MD
More informationThe Need for Accurate Lung Cancer Staging
The Need for Accurate Lung Cancer Staging Peter Baik, DO Thoracic Surgery Cancer Treatment Centers of America Oklahoma Osteopathic Association 115th Annual Convention Financial Disclosures: None 2 Objectives
More informationLoco-regional Recurrence
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer AGO AGO e. e. V. V. Loco-regional Recurrence Loco-regional Recurrence Version 2002: Brunnert / Simon Versions 2003 2012: Audretsch
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationColumbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org
Columbia University Mesothelioma Center www.mesocenter.org Multimodal clinical trials, treatment (surgery, radiation, chemotherapy) Peritoneal mesothelioma program Immunotherapy translational, experimental
More informationبسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
More informationAdiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced
More informationADJUVANT TREATMENT CLINICAL EVALUATION NEOADJUVANT TREATMENT
te: Consider Clinical Trials as treatment options for eligible patients. Referral to a center with both pediatric oncology and orthopedic surgery is essential. CLINICAL EVALUATION This practice algorithm
More information.org. Osteochondroma. Solitary Osteochondroma
Osteochondroma Page ( 1 ) An osteochondroma is a benign (noncancerous) tumor that develops during childhood or adolescence. It is an abnormal growth that forms on the surface of a bone near the growth
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationCorporate Medical Policy
Corporate Medical Policy Intensity Modulated Radiation Therapy for Tumors of the Central File Name: Origination: Last CAP Review: Next CAP Review: Last Review: intensity_modulated_radiation_therapy_for_tumors
More informationCorso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited
More informationCase Number: RT2009-124(M) Potential Audiences: Intent Doctor, Oncology Special Nurse, Resident Doctor
Renal Cell Carcinoma of the Left Kidney Post Radical Surgery with pt4 Classification with Multiple Lung and Single Brain Metastases: the Role and Treatment Consideration of Radiotherapy Case Number: RT2009-124(M)
More informationSMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
More informationA PATIENT S GUIDE TO ABLATION THERAPY
A PATIENT S GUIDE TO ABLATION THERAPY THE DIVISION OF VASCULAR/INTERVENTIONAL RADIOLOGY THE ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL Treatment options for patients with cancer continue to expand, providing
More informationProtein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
More informationTreatment of mesothelioma in Bloemfontein, South Africa
European Journal of Cardio-thoracic Surgery 24 (2003) 434 440 www.elsevier.com/locate/ejcts Treatment of mesothelioma in Bloemfontein, South Africa W.J. de Vries*, M.A. Long Cardiothoracic Department,
More informationMetastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy
Metastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy Sarah Hutto,, MSIV Marc Underhill, M.D. January 27, 2009 Past History 45 yo female
More informationINTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project Data Forms and Fields in CRAB Electronic Data Capture System - Reduced Set - Pivotal data elements for developing
More informationPathologic Assessment Of The Breast And Axilla After Preoperative Therapy
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof
More informationGoals and Objectives: Breast Cancer Service Department of Radiation Oncology
Goals and Objectives: Breast Cancer Service Department of Radiation Oncology The breast cancer service provides training in the diagnosis, management, treatment, and follow-up of breast malignancies, including
More information.org. Metastatic Bone Disease. Description
Metastatic Bone Disease Page ( 1 ) Cancer that begins in an organ, such as the lungs, breast, or prostate, and then spreads to bone is called metastatic bone disease (MBD). More than 1.2 million new cancer
More informationNEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
More informationPrinciples of Radiation Therapy A Bapsi Chakravarthy, MD Associate e P rofessor Professor Radiation Oncology
Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate Professor Radiation Oncology Disclosure Information I have no financial relationships to disclose relevant to the conten of this presentation.
More informationCHAPTER 2. Neoplasms (C00-D49) March 2014. 2014 MVP Health Care, Inc.
Neoplasms (C00-D49) March 2014 2014 MVP Health Care, Inc. CHAPTER SPECIFIC CATEGORY CODE BLOCKS C00-C14 Malignant neoplasms of lip, oral cavity and pharynx C15-C26 Malignant neoplasms of digestive organs
More informationDefinitive Treatment of Poor-Risk Patients with Stage I Lung Cancer. A Single Institution Experience
ORIGINAL ARTICLE Definitive Treatment of Poor-Risk Patients with Stage I Lung Cancer A Single Institution Experience Michael Hsie, MD,* Stefania Morbidini-Gaffney, MD,* Leslie J. Kohman, MD, Elisabeth
More informationLocal control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins
The American Journal of Surgery 190 (2005) 521 525 George Peter s Award Winner Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins Heather R. MacDonald,
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationSurgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科
Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科 Papillary microcarcinoma of thyroid Definition latent aberrant thyroid occult thyroid carcinoma latent papillary carcinoma)
More informationThe Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in Breast Cancer
BIT's 4th World Cancer Congress 2011 People s Republic of China Dalian The Di Bella Method (DBM) improves Survival, Objective Response and Performance Status in treated with DBM therapy Retrospective observational
More informationSurgical Treatment of Bone Metastases in Patients With Breast Cancer
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH Number 396, pp. 191 196 2002 Lippincott Williams & Wilkins, Inc. Surgical Treatment of Bone Metastases in Patients With Breast Cancer Hans Roland Dürr, MD*; Peter
More informationManagement of Primary Chest Wall Tumors: 14 Years Clinical Experience
ORIGINAL ARTICLE Management of Primary Chest Wall Tumors: 14 Years Clinical Experience Po-Kuei Hsu 1, Han-Shui Hsu 1 *, Hui-Chen Lee 2, Chih-Cheng Hsieh 1, Yu-Chung Wu 1, Liang-Shun Wang 1, Biing-Shiun
More informationCarcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology
Carcinoma of the Cervix Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Treatment Treatment Microinvasive (Stage IA1): Simple (extrafascial) hysterectomy/cone
More informationSurgical therapy of. who should be operated
SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, 13th and 14th January 2012 Surgical therapy of mesothelioma, who should be operated Walter Weder MD Professor of Surgery University Hospital Zurich
More informationRadioterapia panencefalica. Umberto Ricardi
Radioterapia panencefalica Umberto Ricardi Background Systemic disease to the brain is unfortunately a quite common event Radiotherapy, especially with the great technical development during the past decades,
More informationRetroperitoneal sarcomas - A retrospective study.
Biomedical Research 2009; 20 (1):1-6 Retroperitoneal sarcomas - A retrospective study. Mohammed Al-Qahtani and Alhasan Asiri Department of Surgery, College of Medicine, King Khalid University, Abha, Saudi
More informationDifferences in type of comorbidity and complications in young and elderly
Differences in type of comorbidity and complications in young and elderly 5.1 Relation between age, comorbidity, and complications in patients undergoing major surgery for head and neck cancer Peters TTA
More informationStomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda
Stomach (Gastric) Cancer Prof. M K Mahajan ACDT & RC Bathinda Gastric Cancer Role of Radiation Layers of the Stomach Mucosa Submucosa Muscularis Serosa Stomach and Regional Lymph Nodes Stomach and Regional
More informationPRINIPLES OF RADIATION THERAPY Adarsh Kumar. The basis of radiation therapy revolve around the principle that ionizing radiations kill cells
PRINIPLES OF RADIATION THERAPY Adarsh Kumar The basis of radiation therapy revolve around the principle that ionizing radiations kill cells Radiotherapy terminology: a. Radiosensitivity: refers to susceptibility
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationResults of Surgical Treatment for Small Cell Lung Cancers
NAOSITE: Nagasaki University's Ac Title Author(s) Results of Surgical Treatment for S Ayabe, Hiroyoshi; Nakamura, Akihiro Hara, Shinsuke; Tagawa, Yutaka; Kaw Citation Acta medica Nagasakiensia. 1994, 39
More informationSentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds
Sentinel Lymph Node Mapping for Endometrial Cancer Locke Uppendahl, MD Grand Rounds Endometrial Cancer Most common gynecologic malignancy in US estimated 52,630 new cases in 2014 estimated 8,590 deaths
More informationCancer treatment. TOP EUROPEAN CANCER EXPERTISE The path to recovery
Cancer treatment TOP EUROPEAN CANCER EXPERTISE The path to recovery 0% LAND OF HIGH QUALITY HEALTHCARE Located in Finland, a land of high quality healthcare, Helsinki University Hospital is regarded as
More informationManagement of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs Michael Alvarado, MD Associate Professor of Surgery University of California San Francisco Case Study 59 yo woman with new palpable
More informationReceptor conversion in distant breast cancer metastases. Breast cancer metastases: A spitting image of their primary?
Receptor conversion in distant breast cancer metastases Breast cancer metastases: A spitting image of their primary? Introduction Breast cancer is the leading cause of female cancer death worldwide (13,000
More informationStage IV Renal Cell Carcinoma. Changing Management in A Comprehensive Community Cancer Center. Susquehanna Health Cancer Center
Stage IV Renal Cell Carcinoma Changing Management in A Comprehensive Community Cancer Center Susquehanna Health Cancer Center 2000 2009 Warren L. Robinson, MD, FACP January 27, 2014 Introduction 65,150
More informationPATIENT INFORMATION ABOUT ADJUVANT THERAPY AFTER THE WHIPPLE OPERATION FOR ADENOCARCINOMA ( CANCER ) OF THE PANCREAS AND RELATED SITES.
PATIENT INFORMATION ABOUT ADJUVANT THERAPY AFTER THE WHIPPLE OPERATION FOR ADENOCARCINOMA ( CANCER ) OF THE PANCREAS AND RELATED SITES. Radiation Oncology Sidney Kimmel Cancer Center at Johns Hopkins Last
More informationSBRT (Elekta), 45 Gy in fractions of 3 Gy 3x/week for 5 weeks (N=22) vs.
Uitgangsvraag 6: Wat is de plaats van stereotactische radiotherapiebehandeling (SBRT) bij HCC patiënten? Primaire studies I Study ID II Method III Patient characteristics IV Intervention(s) V Results primary
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationOverview of Gynaecologic Cancer
Overview of Gynaecologic Cancer Stuart Salfinger Gynaecologic Oncologist St John of God Hospital King Edward Memorial Hospital Cervical Cancer Cervical Cancer Risk HPV Smoking?OCP Cervical Cancer Symptoms
More informationPrognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.
Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or
More informationLocal Coverage Determination (LCD): MolDX: Breast Cancer Assay: Prosigna (L36125)
Local Coverage Determination (LCD): MolDX: Breast Cancer Assay: Prosigna (L36125) Contractor Information Contractor Name Palmetto GBA LCD Information Document Information LCD ID L36125 Original ICD-9 LCD
More informationMale. Female. Death rates from lung cancer in USA
Male Female Death rates from lung cancer in USA Smoking represents an interesting combination of an entrenched industry and a clearly drug-induced cancer Tobacco Use in the US, 1900-2000 5000 100 Per Capita
More informationUpdate on Mesothelioma
November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical
More informationDoes my patient need more therapy after prostate cancer surgery?
Does my patient need more therapy after prostate cancer surgery? Contact the GenomeDx Patient Care Team at: 1.888.792.1601 (toll-free) or e-mail: client.service@genomedx.com Prostate Cancer Classifier
More informationNCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
More informationClinical Management Guideline Management of locally advanced or recurrent Renal cell carcinoma. Protocol for Planning and Treatment
Protocol for Planning and Treatment The process to be followed in the management of: LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA Patient information given at each stage following agreed information
More informationPrimary -Benign - Malignant Secondary
TUMOURS OF THE LUNG Primary -Benign - Malignant Secondary The incidence of lung cancer has been increasing almost logarithmically and is now reaching epidemic levels. The overall cure rate is very low
More informationThe Whipple Operation for Pancreatic Cancer: Optimism vs. Reality. Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006
The Whipple Operation for Pancreatic Cancer: Optimism vs. Reality Franklin Wright UCHSC Department of Surgery Grand Rounds September 11, 2006 Overview Pancreatic ductal adenocarcinoma Pancreaticoduodenectomy
More information